“Yuge” news. There’s now a MAHA pill, though the seller took some liberties with the acronym. Send news tips and male-enhancement suggestions to John.Wilkerson@statnews.com or John_Wilkerson.07 on ...
Today, a story about the regulatory challenges behind the Neuralink hype.
FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and one of his deputies, Vinay ...
Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more
In his State of the Union address, President Trump claimed he had brought U.S. prescription drug costs from the highest in the world to the lowest ...
The FDA’s recent rejection of a rare disease cell therapy — despite prior internal support and an approval in Europe — is prompting questions about whether the agency’s rhetoric matches its regulatory ...
An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared ...
Paul Offit, a renowned vaccine inventor and former CDC adviser, has been asked three times to debate health secretary Robert F. Kennedy Jr., he said yesterday at a webinar hosted by MedPage Today.
Xenon Pharmaceuticals is developing a drug for the most common type of seizure experienced by people with epilepsy. Here's ...
Her son Ben, she learned, had mucopolysaccharidosis (MPS) type 2, or Hunter Syndrome, one of a group of rare diseases that is ...
Thirty years after scientists demonstrated how brain implants can help rhesus monkeys move robotic limbs using only their ...
Debra Manetta is a writer and certified life coach in New Rochelle, N.Y., and the sibling of a brother who lived with schizophrenia. She also brings experience as a parent of a child with ...
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results